In a week blending regulatory wins, trade optimism, and robust earnings, several Indian stocks grabbed headlines. From Aurobindo Pharma’s clean US FDA inspection to Kalyan Jewellers’ stellar profits, these updates signal resilience amid global uncertainties. Meanwhile, auto players like Tata Motors and Bharat Forge eye US tariff relief, while IDBI Bank’s privatization inches forward.
Aurobindo Pharma led the pharma pack with a flawless US FDA inspection at its subsidiary Eugia Pharma Specialities’ Unit-III in Telangana. The audit, spanning January 27 to February 6, 2026, at the formulation facility in Pashamylaram, ended without observations. This is a big deal for Aurobindo, whose US market reliance makes FDA nods critical. Unit-III focuses on injectables and APIs, key to Aurobindo’s $1.5 billion+ US revenue stream. Past inspections have flagged issues—recall a 2023 Form 483 with 10 observations at another site—but this zero-observation outcome boosts credibility. Shares jumped 4-5% post-news, reflecting investor relief. Analysts at Motilal Oswal note it de-risks near-term US approvals, potentially accelerating launches in high-margin generics like oncology drugs. With US biosimilars heating up, Eugia’s peptide capabilities position Aurobindo for growth, targeting 15-20% FY26 revenue CAGR.
Shifting gears to autos, Tata Motors’ Jaguar Land Rover (JLR) stands out with heavy US exposure—33% of volumes and 86% of Tata’s FY25 passenger vehicle revenue. Hopes for US trade barrier easing, amid talks of tariff reductions, could lift JLR’s pricing power and demand. Luxury SUVs like Range Rover face 25% duties now; cuts would slash costs, aiding margins already at 12-14%. Tata shares rose 2%, but risks linger—China supply chain woes and EV transitions. Sona BLW Precision Forgings, with 40% US revenue from EV drivelines for players like Tesla, is even more directly poised. Lower tariffs mean fatter exports of gears and shafts, improving competitiveness against local US suppliers. Bharat Forge, at 38% North America revenue, supplies forgings to GM and Cummins; tariff relief eases the 10-15% cost hit exporters face, potentially hiking EBITDA margins by 100-200 bps.
PB Fintech doused fundraising rumors, clarifying in a filing that reports of a Qualified Institutional Placement (QIP) are “factually untrue.” Neither management nor board is mulling equity raises, calming fears of dilution for Policybazaar shareholders. The fintech’s stock dipped 1% initially but stabilized; with 30% YoY revenue growth in Q3 FY26, focus shifts to profitability. Investors welcome the denial—QIPs often signal cash crunches—reinforcing PB’s debt-free status and 25% market share in insurance broking.
IDBI Bank’s privatization saga advanced as DIPAM confirmed receiving financial bids. The government’s stake sale (60.5% plus management control) now enters evaluation, with Kotak Mahindra Bank and Fairfax India as frontrunners per sources. This 18-year delay-breaker could unlock ₹30,000 crore value, drawing private capital to boost IDBI’s 5% CASA ratio and retail lending. Shares surged 6%, hitting two-year highs. Success here sets precedents for other PSUs, signaling Modi’s divestment push amid fiscal pressures.
Jewellery shone brightest with Kalyan Jewellers’ Q3 blockbuster: net profit soared 90% YoY to ₹416.2 crore on 42% revenue growth to ₹10,343 crore. EBITDA jumped 74% to ₹750 crore (7.3% margin vs. 5.9%), fueled by 20% same-store sales rise, wedding demand, and 100+ new stores. Gold price hedges offset input costs, while expansion into Tier-2 cities like Thrissur drives scale. Margins beat peers like Titan (6.5%); brokerages like HDFC Securities hike targets to ₹650/share, citing 25% FY26 PAT growth.
Contrast this with Sula Vineyards’ woes—fifth straight profit drop in Q3, with revenue and EBITDA sliding due to Karnataka destocking. India’s top winemaker cited tactical inventory cuts in its No. 2 market (20% sales), but volume declines persist amid premiumization lags. Net profit halved; shares fell 3%. Recovery hinges on urban demand and new launches, but competition from United Spirits bites.
Market Implications
These snippets paint a bullish sectoral mosaic. Pharma’s FDA wins counter US pricing pressures, autos gain from trade tailwinds (US auto imports up 10% FY25), and consumer plays like Kalyan tap festive momentum. Banking privatization adds PSU reform spice. Risks? Geopolitics, rupee volatility (at ₹84/USD), and El Niño’s agri impact. Nifty50 eyes 25,000; these stocks could outperform.
Benchmark indices closed flat Friday, but selective buying lifted these names 2-6%. Investors should watch US policy shifts and Q4 earnings for sustained momentum.
